Skip to content

The Sleep Characteristics of Patients with Mild Cognitive Impairment and the Effects of Repetitive Transcranial Magnetic stimulation on their Sleep and Cognitive Function

The Sleep Characteristics of Patients with Mild Cognitive Impairment and the Effects of Repetitive Transcranial Magnetic stimulation on their Sleep and Cognitive Function

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052124
Enrollment
Unknown
Registered
2021-10-19
Start date
2017-10-01
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Interventions

active rTMS group :repetitive transcranial magnetic stimulation (rTMS)
sham rTMS group:sham stimulation
Healthy normal group (NC):none

Sponsors

Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The inclusion criteria for MCI group: (1) Satisfaction of the diagnostic criteria in Petersen (2004) for MCI; (2) Aged >= 60 years; (3) Disease course >= 6 months; (4) Mini-Mental State Examination (MMSE) score >= 24; (5) Montreal Cognitive Assessment (MoCA-CS) score = 60 years; (2) No cognitive complaint; (3) Mini-Mental State Examination (MMSE) score >= 24; (4) Montreal Cognitive Assessment (MoCA-CS) score <= 26; (5) 20-item Activities of Daily Living (ADL) score < 24. Both groups were matched for age, gender, and years of education.

Exclusion criteria

Exclusion criteria: The exclusion criteria for both groups were: 1. History of brain injury (e.g., cerebrovascular disease, epilepsy, Alzheimer's disease, Parkinson's disease or intracranial tumor); 2. Presence of psychiatric conditions (e.g., major depression, schizophrenia); 3. History of prolonged alcohol or drug abuse during the past 6 months; 4. Presence of severe or unstable systemic disorders (e.g., heart, liver, kidney, endocrine, hematologic or respiratory disease); 5. Communication difficulties between participants and researchers; 6. Incapability of undergoing head MRI scan; 7. Poor adherence to therapy, as assessed using the Morisky Medication Adherence Scale-8 (MMAS-8; maximum score: 8points); and 8. Participating in other clinical study.

Design outcomes

Primary

MeasureTime frame
polysomnography (PSG) parameters;the Pittsburgh Sleep Quality Index (PSQI);Epworth sleepiness scale (ESS);insomnia severity index (ISI);Mini-Mental State Scale (MMSE);Montreal Cognitive Assessment (MoCA);

Countries

China

Contacts

Public ContactYingchun Xiao

Fujian Medical University Union Hospital

13365910685@163.com+86 13365917986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026